Literature DB >> 33108697

Reassessing Sarcopenia in Hypertension: STAR and ACE Inhibitors Excel.

Ayşe Merve Ata1, Murat Kara2, Timur Ekiz3, Özgür Kara4, Mehmet Ali Culha2, Vincenzo Ricci5, Esra Gizem Koyuncu2, Fırat Özcan6, Bayram Kaymak2, Levent Özçakar2.   

Abstract

BACKGROUND: Hypertension and sarcopenia are commonly seen in older adults. The renin-angiotensin system and the therapeutic use of angiotensin-converting enzyme (ACE) inhibitors have been on the agenda of sarcopenia in different perspectives. Our aim was to explore the frequency of sarcopenia in patients with hypertension and to investigate the association between the use of ACE inhibitors and sarcopenia.
METHODS: A total of 272 community-dwelling adults were recruited. Anterior thigh muscle thickness was measured by ultrasound. Handgrip strength, gait speed, and chair stand test were evaluated. Low muscle mass was diagnosed in the presence of low sonographic thigh adjustment ratio (STAR) values and sarcopenia was diagnosed if low STAR values were coupled with low functional tests.
RESULTS: 136 subjects (50.0%) had no comorbid disease; 102 (37.5%) had one, 21 (7.7%) had two, nine (3.3%) had three and four (1.5%) had four comorbid diseases. Both low muscle mass (41.9% vs 13.2%) and sarcopenia (32.2% vs 7.8%) were more commonly seen in hypertensive when compared with normotensive older adults. Subgroup analysis of older adults with hypertension revealed that sarcopenia was less prevalent (P = .003) in patients using ACE inhibitors (8.7%) than those using angiotensin II receptor blockers (48.7%) and other antihypertensive drugs (46.4%). After binary logistic regression analyses; only the presence of hypertension seemed to independently predict the development of sarcopenia in older adults [OR = 6.5 (95% CI: 2.4-17.8, P < .001)].
CONCLUSIONS: Sarcopenia is highly prevalent in hypertensive older adults. Amongst many antihypertensive medications, ACE inhibitors seem to have favourable effects on both disorders.
© 2020 John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 33108697     DOI: 10.1111/ijcp.13800

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  5 in total

Review 1.  Rewinding sarcopenia: a narrative review on the renin-angiotensin system.

Authors:  Timur Ekiz; Murat Kara; Ayşe Merve Ata; Vincenzo Ricci; Özgür Kara; Fırat Özcan; Levent Özçakar
Journal:  Aging Clin Exp Res       Date:  2021-01-04       Impact factor: 3.636

2.  Homing in on cognition with cross-sectional analysis of sarcopenia-related measurements: the SARCOG study.

Authors:  Özgür Kara; Murat Kara; Bayram Kaymak; Tuğçe Cansu Kaya; Beyza Nur Çıtır; Mahmut Esad Durmuş; Esra Durmuşoğlu; Yahya Doğan; Tülay Tiftik; Gökhan Turan; Eda Gürçay; Pelin Analay; Hasan Ocak; Fatıma Edibe Şener; Levent Özçakar
Journal:  Aging Clin Exp Res       Date:  2022-05-18       Impact factor: 4.481

3.  Letter to the Editor: Cervical Paraspinal Muscle Fatty Degeneration is Not Associated with Muscle Cross-Sectional Area: Qualitative Assessment is Preferable for Cervical Sarcopenia.

Authors:  Fevziye Ünsal Malas; Murat Kara; Levent Özçakar
Journal:  Clin Orthop Relat Res       Date:  2021-08-01       Impact factor: 4.755

4.  Serum Sestrin-1 Concentration Is Higher in Frail than Non-Frail Older People Living in Nursing Homes.

Authors:  Begoña Sanz; Chloe Rezola-Pardo; Haritz Arrieta; Ana Belén Fraile-Bermúdez; Janire Alonso-Puyo; Irene Molano; Ana Rodriguez-Larrad; Jon Irazusta
Journal:  Int J Environ Res Public Health       Date:  2022-01-19       Impact factor: 3.390

5.  Diagnosing sarcopenia: Functional perspectives and a new algorithm from the ISarcoPRM.

Authors:  Murat Kara; Bayram Kaymak; Walter Frontera; Ayşe Merve Ata; Vincenzo Ricci; Timur Ekiz; Ke-Vin Chang; Der-Sheng Han; Xanthi Michail; Michael Quittan; Jae-Young Lim; Jonathan F Bean; Franco Franchignoni; Levent Özçakar
Journal:  J Rehabil Med       Date:  2021-06-21       Impact factor: 2.912

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.